Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT01751425
What this trial is testing

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Who this might be right for
Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelogenous Leukemia, BCR-ABL1 Positive in RemissionMinimal Residual Disease+1 more
M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Study completedNCT01207440
What this trial is testing

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Chronic Myeloid LeukemiaPh+ Acute Lymphoblastic Leukemia
Ariad Pharmaceuticals 449
Large-scale testing (Phase 3)Active Not RecruitingNCT05456191
What this trial is testing

Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

Who this might be right for
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Novartis Pharmaceuticals 568
Testing effectiveness (Phase 2)Ended earlyNCT00644878
What this trial is testing

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

Who this might be right for
Chronic Myelogenous Leukemia - Chronic Phase
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Study completedNCT00171249
What this trial is testing

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Who this might be right for
Philadelphia Positive Chronic Myeloid LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia
Novartis Pharmaceuticals 293
Early research (Phase 1)Study completedNCT02081378
What this trial is testing

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Who this might be right for
Chronic Myelogenous LeukemiaPhiladelphia Chromosome-positive Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals 326
Testing effectiveness (Phase 2)Study completedNCT00171158
What this trial is testing

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

Who this might be right for
Philadelphia Chromosome Positive CML
Novartis Pharmaceuticals 260
Large-scale testing (Phase 3)Looking for participantsNCT03459534
What this trial is testing

The Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Who this might be right for
Chronic Myeloid Leukemia, Chronic PhaseCML, Chronic PhaseCML, Refractory+1 more
Il-Yang Pharm. Co., Ltd. 173
Testing effectiveness (Phase 2)UnknownNCT03241199
What this trial is testing

The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia

Who this might be right for
Chronic Myeloid LeukemiaPhiladelphia Chromosome Positive CML
The University of Hong Kong 15
Early research (Phase 1)Ended earlyNCT00464113
What this trial is testing

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

Who this might be right for
Chronic Myeloid LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-Positive
Exelixis 49
Large-scale testing (Phase 3)Active Not RecruitingNCT03722420
What this trial is testing

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Who this might be right for
Chronic Myeloid Leukemia, Chronic Phase
Il-Yang Pharm. Co., Ltd. 238
Early research (Phase 1)Ended earlyNCT02782403
What this trial is testing

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia (CML)Blast Phase Chronic Myelogenous Leukemia (CML)Chronic Phase Phase Chronic Myelogenous Leukemia (CML)+1 more
M.D. Anderson Cancer Center 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT03147612
What this trial is testing

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia With BCR-ABL1+3 more
M.D. Anderson Cancer Center 22
Testing effectiveness (Phase 2)UnknownNCT00199186
What this trial is testing

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Philadelphia Positive Acute Lymphoblastic LeukemiaLymphoid Blastic Phase of Chronic Myeloid Leukemia
Johann Wolfgang Goethe University Hospital
Testing effectiveness (Phase 2)Study completedNCT00858806
What this trial is testing

Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy

Who this might be right for
Chronic Myeloid Leukemia
Università degli Studi di Brescia 78
Testing effectiveness (Phase 2)Study completedNCT00381550
What this trial is testing

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic Phase Chronic Myelogenous Leukemia+7 more
National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT00103701
What this trial is testing

BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

Who this might be right for
Leukemia, Myeloid, Chronic-phaseLeukemia, Lymphoblastic, Acute, Philadelphia-positive
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Study completedNCT00015860
What this trial is testing

STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia

Who this might be right for
Leukemia
Jonsson Comprehensive Cancer Center
Large-scale testing (Phase 3)Study completedNCT00265837
What this trial is testing

Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+3 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 72
Early research (Phase 1)Ended earlyNCT00500006
What this trial is testing

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Who this might be right for
Chronic Myelogenous LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-Positive
Merck Sharp & Dohme LLC 3
Next Page